Cannabics Pharmaceuticals’ study shows lower tumor rate in mice

Study results released Tuesday by Bethesda-based Cannabics Pharmaceuticals Inc., a developer of cancer related cannabinoid-based medicine, showed a 33% decrease in tumor growth in mice in its drug candidate RCC-33 for the treatment of colorectal cancer. Eyal Barad, Cannabics Pharmaceuticals' co-founder and CEO, said the outlook of the oncology market puts this sector's therapeutics sales forecast ...

To purchase a reprint of this article, contact reprints@thedailyrecord.com.

Leave a Reply

Your email address will not be published. Required fields are marked *